Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1984 Jul;81(13):4178–4182. doi: 10.1073/pnas.81.13.4178

Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody.

R Szigeti, D Sulitzeanu, G Henle, W Henle, G Klein
PMCID: PMC345392  PMID: 6330746

Abstract

Soluble membrane fractions derived from Raji cells trigger lymphocytes of Epstein-Barr virus (EBV)-seropositive, but not EBV-seronegative, individuals to release a lymphokine that inhibits leukocyte migration. The reaction can be blocked by the sera of patients with EBV-DNA-carrying tumors, Burkitt lymphoma, or nasopharyngeal carcinoma. Absorption of these sera with EBV-positive, but not EBV-negative, cells abrogates their blocking activity. These findings suggest that the antigen responsible for the leukocyte migration inhibition reaction is an EBV-encoded or an EBV-induced membrane component. The antigen is not identical with EBV-associated nuclear antigen or any other known antibody-detected EBV antigen.

Full text

PDF
4178

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Henle G., Henle W., Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer. 1971 Sep 15;8(2):272–282. doi: 10.1002/ijc.2910080212. [DOI] [PubMed] [Google Scholar]
  4. Klein G., Giovanella B., Westman A., Stehlin J. S., Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975;5(6):319–334. doi: 10.1159/000149930. [DOI] [PubMed] [Google Scholar]
  5. Klein G., Lindahl T., Jondal M., Leibold W., Menézes J., Nilsson K., Sundström C. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A. 1974 Aug;71(8):3283–3286. doi: 10.1073/pnas.71.8.3283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  8. Rickinson A. B., Moss D. J., Wallace L. E., Rowe M., Misko I. S., Epstein M. A., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981 Nov;41(11 Pt 1):4216–4221. [PubMed] [Google Scholar]
  9. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Szigeti R., Bókay J., Révész T., Schuler D. Phytohaemagglutinin-induced leukocyte migration inhibition and phytohaemagglutinin skin test for screening the cell-mediated immune response in children. Allergy. 1980 Oct;35(7):557–562. doi: 10.1111/j.1398-9995.1980.tb01805.x. [DOI] [PubMed] [Google Scholar]
  11. Szigeti R., Luka J., Klein G. Leukocyte migration inhibition studies with Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor. Cell Immunol. 1981 Mar 1;58(2):269–276. doi: 10.1016/0008-8749(81)90220-3. [DOI] [PubMed] [Google Scholar]
  12. Szigeti R., Luka J., Sternås L., Klein G. Migration inhibition caused by EBV-specific 48K subcomponent of EBNA and the associated 53K cellular protein. Int J Cancer. 1982 Apr 15;29(4):413–416. doi: 10.1002/ijc.2910290409. [DOI] [PubMed] [Google Scholar]
  13. Szigeti R., Masucci M. G., Henle W., Henle G., Purtilo D., Klein G. Effect of different Epstein-Barr virus-determined antigens (EBNA, EA, and VCA) on the leukocyte migration of healthy donors and patients with infectious mononucleosis and certain immunodeficiencies. Clin Immunol Immunopathol. 1982 Jan;22(1):128–138. doi: 10.1016/0090-1229(82)90029-0. [DOI] [PubMed] [Google Scholar]
  14. Szigeti R., Timár L., Révész T. Leukocyte migration inhibition with Epstein-Barr virus negative and positive cell extracts. Allergy. 1980 Mar;35(2):97–103. doi: 10.1111/j.1398-9995.1980.tb01723.x. [DOI] [PubMed] [Google Scholar]
  15. Szigeti R., Volsky D. J., Luka J., Klein G. Membranes of EBV-carrying virus nonproducer cells inhibit leukocyte migration of EBV-seropositive but not seronegative donors. J Immunol. 1981 May;126(5):1676–1679. [PubMed] [Google Scholar]
  16. van Santen V., Cheung A., Kieff E. Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1930–1934. doi: 10.1073/pnas.78.3.1930. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES